The vitamin D receptor (VDR) activation (by the VDR ligand calcipotriol, a potent and nonhypercalcemic vitamin D analog) also holds promise in the stromal-reprogramming strategy, as it increases intratumoral gemcitabine delivery, reduces tumor volume and increases mouse survival compared to chemotherapy alone in PDAC [292]. Here, VDR is linked to neoplasm.